1. Eli Lilly's GLP-1 market dominance is supported by superior efficacy and strong manufacturing investments, positioning it as a leader alongside Novo Nordisk with forecasted revenue growth to $75B by 2027. 2. A conservative valuation model estimates Eli Lilly's stock to achieve a 25% CAGR over two years, with a fair price target of $1,200 by January 2027. 3. Key risks include competition from emerging GLP-1 drugmakers and potential delays or setbacks in next-gen oral GLP-1 drugs like Orforglipron, but the stock's 25% margin of safety underpins my rating.